ArticleCell biology and toxicology2025
SENP3 alleviates osteoporosis via promoting SIRT3 transcription through the increase of DLX2 stability via SUMO2/3.
Article in Cell biology and toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundRecent studies have indicated a close relationship between SENP3 and osteoporosis. However, the detailed molecular mechanism of SENP3 mediating osteoporosis has not been well studied. The goal of this work was to study the specific mechanism by which SENP3 regulates downstream genes through deSUMOylation and thus affects the progression of osteoporosis.
methodsOsteogenic differentiation was evaluated through osteogenic marker genes, mineralization, and ALP activity, which were detected by qPCR, western blot, and ALP staining assays. Osteoporosis was assessed in OVX mice assessed using qPCR, Micro-CT, and H&E staining assays. The levels of SENP3, DLX2, and SIRT3 were monitored using qPCR and western blot assays. The SUMOylated modification of DLX2 was evaluated using Co-IP and IP assays. The binding of DLX2 to the SIRT3 promoter was confirmed with ChIP, qPCR, dual-luciferase reporter and western blot assays.
resultsSENP3, DLX2, and SIRT3 expressions were decreased in tissues of OVX mice. Mechanically, SENP3 inhibited SUMOylated modification of DLX2 and augmented DLX2 stability. Addition of SENP3 accelerated osteogenic differentiation via regulating DLX2. Moreover, DLX2 bound to SIRT3 promoter and accelerated SIRT3 transcription. DLX2 depletion-induced impeditive effects on osteogenic differentiation were reversed by SIRT3 overexpression. Moreover, DLX2 addition counteracted sh-SENP3-induced inhibitory effect on osteogenic differentiation, which was partially reversed by SIRT3 knockdown. Furthermore, SENP3 alleviated osteoporosis in OVX mice by regulating DLX2/SIRT3 axis.
conclusionAddition of SENP3 accelerated osteogenic differentiation and relieved osteoporosis via increasing SIRT3 transcription by the enhance of DLX2 stability via SUMO2/3.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.